BeOne Medicines (NASDAQ:ONC) SVP Sells 2,666 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 2,666 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the sale, the senior vice president owned 812 shares in the company, valued at approximately $292,320. This trade represents a 76.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The stock was sold at an average price of $323.69, for a total transaction of $337,932.36.
• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82.

BeOne Medicines Stock Down 0.8%

ONC traded down $3.04 during midday trading on Thursday, reaching $356.01. The company’s stock had a trading volume of 355,456 shares, compared to its average volume of 423,158. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The stock’s 50-day moving average is $302.92 and its 200-day moving average is $309.24. The firm has a market capitalization of $39.06 billion, a price-to-earnings ratio of 63.21 and a beta of 0.49. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. As a group, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 EPS for the current year.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne Medicines reported quarterly earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached approximately $1.71 billion, exceeding expectations and representing roughly 30% growth. The results reinforce the company’s commercial momentum. BeOne Medicines Q2 2026 earnings call highlights
• Positive Sentiment: UBS maintained its Buy rating on BeOne Medicines, signaling continued confidence in the company’s growth outlook and oncology portfolio. UBS maintains Buy rating on BeOne Medicines
• Positive Sentiment: BeOne’s collaboration with Revolution Medicines to fund and develop the Phase 3 RAS(ON) program could expand BeOne’s targeted-cancer pipeline and create future commercialization opportunities. Revolution Medicines’ shares rose following the announcement, suggesting investors viewed the deal as strategically meaningful. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
• Negative Sentiment: CEO John Oyler sold 240,810 shares across transactions dated August 10–12 for approximately $86.5 million, substantially reducing his direct ownership. The sales may pressure sentiment, particularly with ONC trading near its 52-week high, although they were executed under a pre-arranged Rule 10b5-1 plan and therefore may not reflect a new negative view of the company. SEC filing on John Oyler’s BeOne Medicines stock sales

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. EFG International AG bought a new stake in BeOne Medicines in the 4th quarter worth about $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $35,000. CWM LLC grew its stake in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines in the fourth quarter worth approximately $61,000. 48.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ONC. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. upped their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Wolfe Research reiterated an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a research note on Monday. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.